Wedbush reissued their outperform rating on shares of Immunome (NASDAQ:IMNM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a $33.00 target price on the stock.
A number of other research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. initiated coverage on shares of Immunome in a research report on Tuesday, April 30th. They set an overweight rating and a $24.00 price objective on the stock. Guggenheim began coverage on shares of Immunome in a research report on Monday, April 15th. They issued a buy rating and a $35.00 price objective on the stock. Finally, Piper Sandler decreased their price objective on shares of Immunome from $27.00 to $23.00 and set an overweight rating for the company in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome presently has an average rating of Buy and an average target price of $29.00.
Get Our Latest Stock Report on Immunome
Immunome Price Performance
Immunome (NASDAQ:IMNM – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. The company had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.62 million. As a group, equities research analysts anticipate that Immunome will post -1.45 earnings per share for the current fiscal year.
Insider Activity at Immunome
In related news, Director Jean Jacques Bienaime bought 2,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were acquired at an average cost of $13.57 per share, for a total transaction of $27,140.00. Following the purchase, the director now directly owns 9,615 shares of the company’s stock, valued at $130,475.55. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 8.60% of the stock is currently owned by company insiders.
Institutional Trading of Immunome
Several institutional investors and hedge funds have recently modified their holdings of the stock. Cerity Partners LLC bought a new stake in Immunome during the 4th quarter valued at $656,000. Jump Financial LLC purchased a new position in shares of Immunome during the fourth quarter valued at $172,000. Mayo Clinic bought a new stake in shares of Immunome in the fourth quarter valued at about $1,161,000. Avidity Partners Management LP purchased a new stake in Immunome in the fourth quarter worth about $14,268,000. Finally, Clear Creek Financial Management LLC purchased a new stake in Immunome in the first quarter worth about $547,000. Institutional investors own 44.58% of the company’s stock.
About Immunome
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Stories
- Five stocks we like better than Immunome
- What is a Death Cross in Stocks?
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- Technology Stocks Explained: Here’s What to Know About Tech
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- Using the MarketBeat Dividend Yield Calculator
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.